ClinicalTrials.Veeva

Menu
A

American Oncology Network | Hematology Oncology Clinic

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Paclitaxel
Bevacizumab
LOXO-305
Atezolizumab
ZEN003694
Sacituzumab
SAR439859
Ibrutinib
Leucovorin
Abiraterone Acetate

Parent organization

This site is a part of American Oncology Network

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

18 of 29 total trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

To evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of radiographic progression-free sur...

Enrolling
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Drug: Fuzuloparib Placebo, Abiraterone acetate and Prednisone
Drug: Fuzuloparib , Abiraterone acetate and Prednisone

Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab...

Active, not recruiting
Small-Cell Lung Cancer
Drug: Atezolizumab
Drug: Lurbinectedin

The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination wi...

Enrolling
Carcinoma, Hepatocellular
Drug: Tiragolumab
Other: Placebo

This study will evaluate the efficacy, safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with selected B-ce...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Mosunetuzumab (Cohorts A-C)
Drug: Mosunetuzumab (Cohorts D-E)

This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of...

Enrolling
Multiple Myeloma
Drug: Selinexor
Drug: Elotuzumab

This is a global, randomized, double-blind, placebo-controlled, multicenter phase 3 clinical trial to compare the efficacy and safety of fruquintinib...

Active, not recruiting
Metastatic Colorectal Cancer
Metastatic Colon Cancer
Drug: Fruquintinib
Drug: Placebo

This is a study of navicixizumab monotherapy or in combination with paclitaxel or irinotecan in patients with advanced cancer. Patients will be enrol...

Enrolling
Gastric Cancer
Ovarian Cancer
Biological: navicixizumab+irinotecan
Biological: navicixizumab monotherapy

The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants...

Active, not recruiting
Leukemia, B-cell
Small Lymphocytic Lymphoma
Drug: Pirtobrutinib
Drug: Ibrutinib

The purpose of this study is to look at the efficacy and safety of Irinotecan liposome injection in combination with other approved drugs used for ca...

Active, not recruiting
Metastatic Adenocarcinoma of the Pancreas
Drug: Leucovorin
Drug: Gemcitabine

The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 in subjects with KRASG12C mutant NSCLC

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: RMC-4630
Drug: Sotorasib

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to ful...

Enrolling
Metastatic Breast Cancer
Drug: Lasofoxifene in combination with abemaciclib
Drug: Fulvestrant in combination with abemaciclib

This is a multicenter, randomized, open label study of high dose interleukin 2 vs high dose interleukin 2 plus entinostat in clear cell RCC patients...

Active, not recruiting
Renal Cell Carcinoma
Drug: Entinostat
Drug: Interleukin-2

Primary Objective:To determine whether amcenestrant per overall survival (os) improves progression free survival (PFS) when compared with an endocrin...

Active, not recruiting
Breast Cancer Metastatic
Drug: Tamoxifen
Drug: Anastrozole

This is a Phase 2 randomized, open-label, two-part, multicenter study with a safety run-in to evaluate efficacy and safety of DKN-01 plus FOLFIRI/FOL...

Active, not recruiting
Colorectal Adenocarcinoma
Colo-rectal Cancer
Drug: Bevacizumab
Drug: FOLFOX

This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare pirtobrutinib (LOXO-30...

Active, not recruiting
Lymphoma, Mantle-Cell
Drug: Ibrutinib
Drug: Pirtobrutinib

The goal of this clinical study is to see if sacituzumab govitecan-hziy (SG) can improve life spans of people with HR+/HER2- metastatic breast cancer...

Active, not recruiting
Locally Advanced or Unresectable Metastatic Breast Cancer
Stage IV Breast Cancer
Drug: Paclitaxel
Drug: Capecitabine

The purpose of this study is to evaluate the safety, tolerability, and antitumor activity of BGB-3245 in participants with advanced or refractory sol...

Enrolling
Solid Tumor
B-Raf Mutation-Related Tumors
Drug: BGB-3245

This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC w...

Enrolling
Metastatic Castration-Resistant Prostate Cancer
Drug: ZEN003694
Drug: Enzalutamide

Trial sponsors

Genentech logo
Gilead Sciences logo
Lilly logo
Loxo Oncology logo
Roche logo
A
Celgene logo
CytomX logo
Eisai logo
HUTCHMED logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems